|Bid||0.00 x 1800|
|Ask||0.00 x 800|
|Day's Range||147.10 - 152.38|
|52 Week Range||92.15 - 174.04|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-0.87%|
|Beta (5Y Monthly)||0.91|
|Expense Ratio (net)||0.46%|
Shares of Ocugen Inc. soared 31.0% in premarket trading Wednesday, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%. Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups. "These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States," said Ocugen Chief Executive Shankar Musunuri. "COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19." Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&P 500 has gained 5.6%.
Shares of Athenex Inc. plummeted 54.6% on very active afternoon trading Monday, enough to be the biggest decliner listed on major U.S. exchanges, after the Food and Drug Administration said the biopharmaceutical company's New Drug Application (NDA) for its metastatic breast cancer treatment, oral paclitaxel plus encequidar, is not ready for approval in its present form. Trading volume spiked to 40.1 million shares, compared with the full-day average of about 1.1 million shares. The company said earlier that the FDA issued a complete response letter (CRL) expressing concerns of a safety risk to patients, and recommended a new clinical trial be conducted. Separately, the company reported a fourth-quarter net loss that widened to $49.5 million, or 53 cents a share, from $21.7 million, or 28 cents a share, in the year-ago period, wider than the FactSet consensus for a per-share loss of 44 cents. Revenue fell 36.5% to $21.8 million, topping the FactSet consensus of $20.7 million. The stock has lost 55.1% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has climbed 40.2% and the S&P 500 has advanced 32.4%.
Shares of Otonomy Inc. plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's disease (vertigo) treatment failed to meet its primary endpoint. "We are disappointed by the top-line results for the primary intent-to-treat population and are undertaking an assessment to understand the difference observed with the per protocol analysis," said Chief Executive David Weber. He said the company's focus turns to the "strong pipeline," highlighted by the "successful" clinical trial results of its tinnitus and hearing loss treatments, with clinical readouts anticipated in mid-2022. Weber said he expects the company's existing cash balance is enough to to achieve the clinical readouts. The stock has rallied 51.8% over the past 12 months through Friday, while the iShares Nasdaq Biotechnology ETF has advanced 35.1% and the S&P 500 has gained 17.1%.